Cervical and Upper Mediastinal Lymph Node Metastasis from Gastrointestinal and Pancreatic Neuroendocrine Tumors: True Incidence and Management - 23/05/12
, George Mayhall, MD e, Lowell B. Anthony, MD b, d, Richard J. Campeau, MD, FACNM c, d, J. Philip Boudreaux, MD, FACS a, d, Eugene A. Woltering, MD, FACS a, dRésumé |
Background |
The incidence, clinical importance, and optimal management of cervical and upper mediastinal lymph node metastasis from gastrointestinal and pancreatic neuroendocrine tumors (NETS) are largely unknown. Historically, cervical nodes have been regarded as asymptomatic and ignored. We hypothesized that these lesions have clinical implications and should be removed surgically.
Study Design |
Consecutive 111In pentetreotide scans (OctreoScan) performed at our institution from May 2008 to October 2010 were reviewed to determine the incidence of cervical and upper mediastinal lymph node metastases among patients with gastrointestinal and pancreatic NETs. The charts of surgically treated patients were reviewed to evaluate the clinical importance of these metastases and the subsequent outcomes of their surgical treatment.
Results |
A total of 161 NET patients presented with positive OctreoScans. Fourteen patients (8.7%) scanned positive for cervical and upper mediastinal lymph node metastasis. Nine patients underwent surgical exploration; 8 had successful removal of their metastatic nodes. Seven had clinical symptoms that resolved after surgery.
Conclusions |
Cervical and upper mediastinal lymph node metastases from gastrointestinal and pancreatic NETs were seen in up to 8.7% of patients. In the past, these metastases were assumed to be insignificant and ignored. Our study clearly demonstrates that most, if not all, such metastases are symptomatic and their clinical implications should not be overlooked. Notably, these metastases can be easily and safely resected using radioguided surgery.
Le texte complet de cet article est disponible en PDF.Plan
| Disclosure Information: Dr Boudreaux has received honoraria for speaking and serving on the Advisory Board of Novartis Pharmaceuticals. All other authors have nothing to declare. |
Vol 214 - N° 6
P. 1017-1022 - juin 2012 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
